Curated news and analysis on clinical trials, drug approvals, and medical research.
Beyond Physician announced the commercial launch of its patent-pending VOICE platform, which uses AI-analyzed physician audio interviews instead of surveys. The company said the platform extracted 560+ data points from a 10-question interview and 9,800+ data points in its first commercial engagement.
A study in the American Journal of Medicine found that U.S. adults with the highest ultraprocessed food intake had higher cardiovascular disease risk. Mean ultraprocessed food intake was 26.1% of total energy.
The Lancet refused a U.S. Senate request for evidence on COVID-19 origins. Purdue Pharma's sentencing was delayed, while insurers moved to reduce prior-authorization paperwork.
More than 2,700 drivers were arrested for drug-related offences in January as authorities expanded roadside inspections and medical testing. Separate road safety checks in Keighley recorded 17 offences, including one drug-driving arrest.
The pharmaceutical manufacturing market is projected to reach $1.24 trillion by 2032, while the continuous manufacturing market is expected to reach $4.2 billion by 2040. Growth is tied to biologic drug demand, digital platforms, automation, and regulatory support.
Anirban Maitra highlighted a talk at NYU Langone Health on milestones in developing RAS tricomplex inhibitors. The presentation also covered ongoing and planned combination approaches.
A UK trial found continuous glucose monitoring improved HbA1c and time in range for adults with type 2 diabetes using basal insulin. Dexcom is also awaiting a Medicare decision on broader CGM coverage for non-insulin users.
Novartis AG has entered into an agreement to sell 1.74 crore shares, or 70.68% of Novartis India, to investors led by ChrysCapital. Novartis India later posted a 4.81% weekly gain even as quarterly profit and net sales declined.
More than 30 approved cell and gene therapies carry prices from nearly $1 million to over $4 million, creating fiscal pressure for Medicaid. A federal access model launched in 2024 aims to centralize outcomes-based contracting.
Morphic Medical’s Reset obesity treatment device received NUB status in Germany, allowing hospitals to seek supplementary reimbursement. The company said U.S. FDA study enrollment is continuing after protocol changes to accelerate recruitment.
Congress rejected the administration’s deepest proposed science cuts, increasing NIH funding by about $415 million to $48.7 billion. NASA and NSF also saw far smaller reductions than proposed.
Calls are growing to bring CAR-T cell therapy to New Zealand as the current trial is set to end later this year. There is no clear path to public availability.
A study suggests a 16-protein blood test, the Sjögren’s protein score, may measure salivary gland inflammation without biopsy. The score correlated with glandular inflammation, antibodies, and extraglandular disease features.
Merck received FDA approval in early February 2026 for KEYTRUDA and KEYTRUDA QLEX in PD-L1-positive platinum-resistant ovarian cancer. The decision marks the first approval of a PD-1 inhibitor regimen for this setting.
Isomorphic Labs said one AI-designed drug, ISM8969, has FDA clearance for human clinical trials. The company’s initial pipeline focuses on oncology candidates.
Zocilurtatug pelitecan showed an overall response rate of 38.2% and a disease control rate of 55.9% in 34 patients with pretreated extrapulmonary neuroendocrine carcinomas. Grade 3 or higher treatment-emergent adverse effects occurred in 30.4% of patients.
Everest Medicines launched VELSIPITY in Mainland China after NMPA approval on February 2, 2026. The first prescription was issued at The First Affiliated Hospital of Sun Yat-sen University.
Medtronic reported interim Affera Sphere-9 data showing 65.5% of VT patients were free from recurrence at six months. The FDA granted Breakthrough Device designation for Sphere-9 and approved a U.S. pivotal IDE.
Researchers developed a lipid nanoparticle gene-editing approach that inserted a full CFTR gene into airway cells and restored 88% to 100% of normal channel function in a cystic fibrosis lab model.
A study in Ophthalmology found tirzepatide use was associated with lower 12-month risk of new or progressive diabetic retinopathy versus lifestyle intervention alone. The analysis included about 174,000 matched patients.
